Contraception News and Research RSS Feed - Contraception News and Research

Mylan releases generic version of Seasonale Tablets in the U.S.

Mylan releases generic version of Seasonale Tablets in the U.S.

Mylan N.V. today announced the U.S. launch of Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg, which is the generic version of Teva's Seasonale Tablets. Mylan's partner Famy Care Ltd. received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. [More]
Novel subdermal implant delivering potent ARV drugs shows promise in stopping HIV

Novel subdermal implant delivering potent ARV drugs shows promise in stopping HIV

Is the end of HIV near? Findings published this week in Antimicrobial Agents and Chemotherapy report that a novel, subdermal implant delivering potent antiretroviral (ARV) drugs shows extreme promise in stopping the spread of HIV. [More]
National survey shows that most women don't know risks or symptoms of stroke

National survey shows that most women don't know risks or symptoms of stroke

A national survey released today by The Ohio State University Wexner Medical Center shows that most women don't know the risks or symptoms females face when it comes to having a stroke. [More]
Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. [More]
Alternative treatment options for uterine fibroids

Alternative treatment options for uterine fibroids

A 47-year-old African-American woman has heavy menstrual bleeding and iron-deficiency anemia. She reports the frequent need to urinate during the night and throughout the day. A colonoscopy is negative and an ultrasonography shows a modestly enlarged uterus with three uterine fibroids, noncancerous growths of the uterus. [More]
Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith presents favorable data from PREVAIL OLE study of Qudexy XR capsules

Upsher-Smith Laboratories, Inc. presented data from a 52-week, open-label extension study (PREVAIL OLE) showing that Qudexy XR (topiramate) extended-release capsules offered a long-term adjunctive treatment option with a favorable tolerability profile for a high proportion of patients with refractory partial-onset seizures (POS). [More]
Studies reveal that dietary supplement can improve reproductive health

Studies reveal that dietary supplement can improve reproductive health

Current statistics on U.S. birth rates from the Centers for Disease Control and Prevention report a continued trend toward delayed motherhood. As fertility gradually declines in the 30s, particularly after age 35, the risk of experiencing difficulty conceiving may increase. In addition to age, there are other common reasons why women may experience difficulties conceiving, including: irregular ovulation cycles and poor egg quality, which may be associated with stress, lifestyle or poor diet. [More]
Contraception access: an interview with Pamela Weir, Chief Operating Officer, Medicines360

Contraception access: an interview with Pamela Weir, Chief Operating Officer, Medicines360

One of the key barriers for women to receiving highly effective and safe contraception is access, because of cost. With LILETTA™ women will have expanded access to an available IUD that is safe and effective when they need or want it... [More]
Mylan announces the U.S. launch of first generic version of Generess Fe tablets

Mylan announces the U.S. launch of first generic version of Generess Fe tablets

Mylan N.V. today announced the U.S. launch of Norethindrone and Ethinyl Estradiol Tablets (Chewable) 0.8 mg/0.025 mg and Ferrous Fumarate Tablets, 75 mg (Chewable), which is the generic version of Warner Chilcott's Generess Fe Tablets. [More]
Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira, Inc., a global leader in biosimilars and the world's leading provider of injectable drugs and infusion technologies, announces the availability of INFLECTRA (infliximab) in Canada, the country's first subsequent entry biologic (SEB) monoclonal antibody (mAb) therapy. [More]
United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. [More]
Researchers one step closer to unraveling complex processes crucial to sperm development

Researchers one step closer to unraveling complex processes crucial to sperm development

Researchers are one step closer to unraveling the extraordinarily complex series of processes that leads to an event crucial to human reproduction: the creation of sperm. [More]
FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

Actavis plc, a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA (levonorgestrel-releasing intrauterine system) by the U.S. Food and Drug Administration for use by women to prevent pregnancy for up to three years. [More]
Bayer expands patient assistance program for intrauterine devices

Bayer expands patient assistance program for intrauterine devices

Bayer HealthCare Pharmaceuticals Inc. today announced the expansion of its patient assistance program for intrauterine devices (IUD). The ARCH (Access and Resources for Contraceptive Health) program will provide Skyla (levonorgestrel-releasing intrauterine system) 13.5 mg and Mirena (levonorgestrel-releasing intrauterine system) 52 mg to low-income women who meet eligibility criteria. [More]
Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S. [More]
Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). [More]
Catholics for Choice calls on Pope Francis to open childcare facilities in Vatican City

Catholics for Choice calls on Pope Francis to open childcare facilities in Vatican City

Today, in light of Pope Francis' comments that he believes "not having children is a selfish choice,"Catholics for Choice suggests that the pope, cardinals, bishops and priests that make up the citizens of Vatican City consider opening and running childcare facilities for the women in the world to give the hierarchy some hands-on experience. [More]
LA BioMed's Christina Wang receives Mayo H. Soley Award for outstanding research work

LA BioMed's Christina Wang receives Mayo H. Soley Award for outstanding research work

Christina Wang, MD, Los Angeles Biomedical Research Institute lead researcher, has received a top honor for her outstanding research work, the Mayo H. Soley Award, at the 2015 Western Regional Meetings of five top research societies in the West. [More]
Providing knowledge about contraception can significantly improve use of isotretinoin

Providing knowledge about contraception can significantly improve use of isotretinoin

Providing women who take a powerful acne drug with a fact sheet about contraception while visiting the dermatologist can significantly improve their awareness of the most effective birth control options and may prevent unintended pregnancies and birth defects that can be caused by the drug, according to a University of Pittsburgh School of Medicine study published Feb. 4 in the journal JAMA Dermatology. [More]
News study finds association between chronic fatigue syndrome and early menopause

News study finds association between chronic fatigue syndrome and early menopause

A newfound link between chronic fatigue syndrome (CFS) and early menopause was reported online today in Menopause, the journal of The North American Menopause Society. [More]
Advertisement
Advertisement